Skip to main content
Article thumbnail
Location of Repository

Evaluation of olopatadine 0.2% in the complete prevention of ocular itching in the conjunctival allergen challenge model

By Kabat AG, Granet DB, Amin D, Tort MJ and Blaiss MS


Alan G Kabat1, David B Granet2, Dina Amin3, Maria J Tort3, Michael S Blaiss41Nova Southeastern University, Fort Lauderdale, FL, USA; 2Shiley Eye Center, University of California San Diego, La Jolla, CA, USA; 3Alcon Research Ltd, Fort Worth, TX, USA; 4University of Tennessee Health Science Center, Memphis, TN, USABackground: Olopatadine hydrochloride ophthalmic solution 0.2% (PATADAY™; Alcon, Fort Worth, TX) (olopatadine 0.2%) is a formulation of a multi-action agent that has been approved for the treatment of ocular itching associated with allergic conjunctivitis when used once daily.Objective: To evaluate olopatadine 0.2% versus its vehicle in the complete prevention of ocular itching in adult patients with allergic conjunctivitis.Methods: This paper presents a post-hoc analysis of subgroup results from a single-center, double-masked, randomized, contralateral eye, conjunctival allergen challenge study. The post-hoc efficacy analysis, conducted with data from patients who instilled olopatadine 0.2% in a single eye and vehicle in the contralateral eye, compared the ability of each study formulation to completely prevent ocular itching at three assessment time points post-instillation. Safety was not reevaluated in the post-hoc analysis.Results: Overall, 40 patients received contralateral instillations of study drug and were included in the post-hoc analysis. At all three post-instillation time points, significantly greater proportions of patients reported itching scores of 0 in the olopatadine 0.2%-treated eye than in the vehicle-treated eye (63%–65% versus 3%–10%, respectively; P < 0.05 for each comparison). Within the previously reported results for the full study, no clinically relevant or statistically significant changes from baseline were observed for patients in regard to visual acuity, ocular signs, or fundus parameters.Conclusion: Olopatadine 0.2% is safe, well tolerated, and superior to vehicle in completely preventing ocular itching that results from allergen exposure following drug instillation in patients with allergic conjunctivitis.Keywords: allergic conjunctivitis, zero-itch, efficacy, safety, CA

Topics: LCC:Ophthalmology, LCC:RE1-994, LCC:Medicine, LCC:R, DOAJ:Ophthalmology, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Dove Press
Year: 2011
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.